LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
It stands to reason that with the large amount of volatility in biotech companies it is worth taking a closer look at biotechs with lower prices per share, as there is plenty much more upside.
This is why we are taking a very close look at Propanc Health Group (OTCQB: PPCH), who through its novel PRP treatment, is working toward clinical trials for pancreatic and ovarian cancers, followed by colorectal cancer.
Over the past year Propanc has made incredible strides toward achieving this goal, and just recently announced they received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year.
In an effort to keep the funding flowing the company announced their Chief Executive Officer, James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company's future plans for growth. Proactive capital raising will help ensure there are no financial hiccups in PPCH's growth. This is huge for investors, and could cause a new influx of investors.
Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 60 years in medicine has been critical in the research and development of PRP anti-cancer treatment. Klaus Kutz, CMO of Propanc, has prepared multiple investigational new drugs (IND) FDA applications, and Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Dr Joseph Chalil, a recent addition to Propanc's Scientific Advisory Board, is a senior executive of Boehringer Ingleheim and a fellow of the American College of Healthcare Executives. The hope is this combination of experience will help them repeat their successes with Propanc.
There are several major events coming up that could be the catalyst for a major spike in share price: a scientific advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), UK, which has been confirmed towards the end of April, followed by a commitment to submit applications for orphan drug designation in the US and EU for pancreatic and ovarian cancers; investors are anticipating some large announcements in the near future and want to be in position to benefit before the secret is out on the enormous potential of PPCH.
With all of this going on it is no wonder that investors are loading the boat on PPCH. Now is not the time to sit on the sidelines.
Here’s a few other lower PPS (price per share) biotechs that have potential to reward investors.
Cerulean Pharma Inc. (NASDAQ: CERU), is expecting results from the FDA which may lead to even more upside for this company that is already on a nice run.
After slightly disappointing quarterly results, VIVUS Inc. (NASDAQ: VVUS) took a small hit, however, recently the stock has been on a tear erasing those losses and adding almost 50% in gains.
CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that an abstract titled, "Clinical and Economic Burden of Bloodstream Infections Following Central Venous Catheter Placement in the Intensive Care Unit" has been selected for a poster presentation at the ISPOR 21st Annual International Meeting to be held May 21-25, 2016 in Washington, DC. Investors have started to take interest in this company leading up to the presentation.
Speaking of share price appreciation ahead of a presentation, shares of Aratana Therapeutics (NASDAQ: PETX) are climbing on heavy trading volume, as the pet therapeutics company said it will present pivotal efficacy and safety data about its galliprant tablets for dogs. The Leawood, KS-based company presented at the American Animal Hospital Association annual conference in Austin on Saturday. Galliprant was approved by the FDA's Center for Veterinary Medicine on March 20 for the control of pain and inflammation associated with osteoarthritis in dogs.
Galena Biopharma, Inc. (NASDAQ: GALE) announced that the 70th qualifying disease free survival (DFS) event has been achieved in the NeuVax™ (nelipepimut-S) Phase 3, PRESENT (Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax is a peptide immunotherapy vaccine currently being evaluated for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $67,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.
Contact:
SOURCE: ACR Communication, LLC
ReleaseID: 438537
